Savolitinib demonstrated the ability to overcome MET-mediated resistance in patients with EGFR-mutant, MET-amplified or c-MET overexpressed NSCLC when combined with osimertinib, and these benefits extended to those with disease that had previously progressed on a prior EGFR–TKI [29,44]. Here, MET is linked to non-small cell lung carcinoma.